Quest Diagnostics (DGX) SVP sells 958 shares and receives new equity awards

Rhea-AI Filing Summary

Quest Diagnostics senior vice president Patrick Plewman reported a mix of stock transactions and equity awards. On February 19, 2026, he completed an open‑market sale of 958 shares of common stock, leaving him with 15,838 shares held directly.

On February 18, 2026, he received a grant of 9,009 non-qualified stock options, which vest in three equal annual installments starting on the first anniversary of the grant date. He was also awarded 1,952 restricted stock units.

That same day, a total of 537 shares of common stock (244 shares at one price and 293 shares at another) were surrendered to the issuer solely to cover tax withholding obligations from vesting restricted stock units. The footnotes state the 958‑share sale was executed under a pre-arranged Rule 10b5‑1 trading plan adopted by Plewman.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plewman Patrick

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP for Diagnostic Services

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/18/2026		A		1,952	A	$0	17,333	D
Common Stock	02/18/2026		F		244(2)	D	$210.01	17,089	D
Common Stock	02/18/2026		F		293(2)	D	$206.99	16,796	D
Common Stock	02/19/2026		S		958(3)	D	$204.83	15,838	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualifed Stock Option (right to buy)	$204.96	02/18/2026		A		9,009		(4)	02/18/2036	Common Stock	9,009	$0	9,009	D

Explanation of Responses:

1. Represents an award of restricted stock units.

2. Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units.

3. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

4. The options vest in three equal annual installments beginning on the first annual anniversary of the grant date.

Remarks:

	Sean D. Mersten, Attorney in Fact for Patrick Plewman	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did DGX executive Patrick Plewman report?

Patrick Plewman reported an open-market sale of 958 Quest Diagnostics shares, multiple equity awards, and tax-related share dispositions. The activity included stock option and restricted stock unit grants, plus shares surrendered back to the company to cover tax withholding from vesting awards.

How many Quest Diagnostics shares did Patrick Plewman sell in this Form 4?

He sold 958 shares of Quest Diagnostics common stock in an open-market transaction. According to the filing, this sale was executed under a pre-arranged Rule 10b5-1 trading plan and left him holding 15,838 shares of common stock directly after the transaction.

What new equity awards did Patrick Plewman receive from Quest Diagnostics (DGX)?

He received 9,009 non-qualified stock options and 1,952 restricted stock units. The options vest in three equal annual installments starting on the first anniversary of the grant date, while the restricted stock units were recorded as an equity award in Quest Diagnostics common stock.

Why were some Quest Diagnostics shares disposed of to the issuer in this filing?

A total of 537 Quest Diagnostics shares were surrendered to the issuer solely to cover tax withholding obligations. These dispositions related to the vesting of restricted stock units and were reported using transaction code F, which reflects tax-withholding transactions rather than open-market sales.

How many Quest Diagnostics shares does Patrick Plewman own after these transactions?

After the reported transactions, Patrick Plewman directly owns 15,838 shares of Quest Diagnostics common stock. This figure reflects his holdings following the 958-share open-market sale and the various equity awards and tax-related share dispositions disclosed in the Form 4 filing.

What does the Rule 10b5-1 trading plan note mean in Plewman’s DGX Form 4?

The filing states that the 958-share sale was executed under a Rule 10b5-1 trading plan adopted by Patrick Plewman. Such plans pre-schedule trades, allowing executives to systematically sell shares according to preset instructions, helping separate trading decisions from later market developments.